Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSALT Peptide for the Prevention of AKI in On-Pump Cardiac Surgery
NCT05879432Phase 2Recruiting
- Sponsor
- Arch Biopartners
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in acute kidney injury (AKI) comparing LSALT Peptide with Placebo (2 arms). Primary endpoint: Percentage of subjects with Acute Kidney Injury at 7 days. Started Mar 2024; status: recruiting.
02
Drugs
LSALT peptide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05879432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879432.